Drugs / Danvatirsen
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT05986240 | May 2024 → Jun 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | Montefiore Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT03819465 | Dec 2018 → May 2023 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03527147 | Jun 2018 → Mar 2021 | diffuse large B-cell lymphoma | Acerta Pharma BV | Completed | No outcome recorded |
| Phase 1 | NCT03421353 | Feb 2018 → Jan 2020 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03394144 | Jan 2018 → Apr 2019 | high grade malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02546661 | Dec 2016 → Mar 2020 overdue | infiltrating bladder urothelial carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02549651 | Jul 2016 → Feb 2019 | diffuse large B-cell lymphoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT01839604 | May 2013 → Feb 2015 | adult hepatocellular carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02499328 | Aug 2015 → Feb 2020 | head and neck squamous cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 25 trials · 1 met primary | ||||||
| Phase 2 | NCT05814666 | May 2023 → Aug 2025 | head and neck squamous cell carcinoma | Flamingo Therapeutics NV | Terminated | No outcome recorded |
| Phase 2 | NCT03794544 | Mar 2019 → Jan 2021 | non-small cell lung carcinoma | MedImmune LLC | Completed | No outcome recorded |
| Phase 2 | NCT03334617 | Dec 2017 → Sep 2024 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02983578 | Mar 2017 → Aug 2025 overdue | colorectal carcinoma, non-small cell lung carcinoma | M.D. Anderson Cancer Center | Active not recruiting | Met primary |
| Phase 2 | NCT02417753 | Apr 2015 → Apr 2016 | digestive system cancer, ovarian cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2019-03-14 | AstraZeneca | Results AstraZeneca showcases next-generation Oncology pipeline addressing unmet patient needs at AACR Annual Meeting astrazeneca.com ↗
Preclinical pharmacodynamic and mechanistic data illustrating how danvatirsen (AZD9150), a STAT3 ASO reverses immunosuppression to produce significant anti-tumour effects, both as monotherapy and in combination with anti-PDL1 (Abstract #3215/25) |
| 2018-10-22 | Ionis Pharmaceuticals | Results Phase 1b/2 Data of Durvalumab Plus Danvatirsen Presented at European Society for Medical Oncology ionis.com ↗
The combination treatment resulted in 7% of patients achieving a complete tumor response and 23% achieving either a partial or complete tumor response. |
| 2017-09-11 | Ionis Pharmaceuticals | Results New Data Presented at European Society for Medical Oncology Meeting Demonstrate Antitumor Activity with IONIS-STAT3-2.5 Rx in Combination with Imfinzi ionis.com ↗
In the study, the combination treatment resulted in encouraging antitumor activity with a safety and tolerability profile supportive of continued development. |
| 2016-04-14 | AstraZeneca | Results AstraZeneca showcases breadth of Oncology portfolio at AACR 2016 Annual Meeting astrazeneca.com ↗
Inhibition of STAT3 with oligonucleotide antisense molecule, AZD9150 increases the chemosensitivity and decreases tumorigenicity of neuroblastoma |
| 2014-11-20 | Ionis Pharmaceuticals | Results ISIS-STAT3 Rx and ISIS-AR Rx Data Presented by AstraZeneca at European Cancer Symposium ionis.com ↗
Results from a Phase 1/2 clinical study presented today provided preliminary evidence of antitumor activity for ISIS-STAT3Rx (AZD9150) in patients with cancer including advanced/metastatic hepatocellular carcinoma (HCC). |
| 2013-06-03 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Reports Encouraging Data on ISIS-STAT3rx in Patients With Cancer ionis.com ↗
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the American Society of Clinical Oncology in Chicago. |
| 2012-10-31 | Ionis Pharmaceuticals | Results Isis Pharmaceuticals Reports Encouraging Interim Phase 1 Data On ISIS-STAT3Rx In Patients With Cancer ionis.com ↗
Interim results of the initial dose escalation study in patients with cancer showed that ISIS-STAT3Rx treatment resulted in clear responses in patients with advanced cancer who were refractory to prior chemotherapy treatment, with an acceptable safety profile. |
All press releases naming this drug 8 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | danvatirsen | “antisense oligonucleotide targeting STAT3 (danvatirsen)” PMID 36270753 ↗ Oct 2022 |
| Known as | AZD9150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03527147 ↗ |
| Known as | ISIS-481464 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297739 ↗ |
| Known as | ISIS-STAT3Rx | “A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma” NCT01839604 ↗ |
| Action | Inhibit | “target and down-regulate expression of human STAT3 mRNA” NCT02417753 ↗ |
| Modality | Antisense oligonucleotide | “AZD9150 is an antisense oligonucleotide designed to target and down-regulate expression of human STAT3 mRNA.” NCT02417753 ↗ |
| Route | Intravenous | “Intravenous infusion over 3 hours.” NCT01839604 ↗ |
| Target | STAT3 | “target and down-regulate expression of human STAT3 mRNA” NCT02417753 ↗ |